Amarin’s REDUCE-IT Analysis Shows Risk-Weighted ApoB Identifies 30% More Residual Risk
AMRN•Amarin presented post hoc REDUCE-IT analysis from 3,485 placebo-arm patients showing risk-weighted apoB metrics averaged 30% above measured apoB, flagging more residual cardiovascular risk in statin-treated patients with elevated triglycerides over 4.9 years. ESC intervention thresholds identified a larger high-risk cohort using RW-apoB versus apoB alone.
1. New REDUCE-IT Post Hoc Analysis
Amarin unveiled a post hoc analysis of the REDUCE-IT trial at the EAS 2026 Congress, focusing on risk-weighted apolipoprotein B (RW-apoB) as a metric to better assess residual cardiovascular risk in statin-treated patients with elevated triglycerides.
2. Study Design and Key Findings
The analysis evaluated 3,485 participants from the placebo arm over a median 4.9-year follow-up, finding RW-apoB levels were approximately 30% higher than measured apoB, and identified more high-risk patients compared with traditional lipid markers.
3. Clinical and Guideline Implications
Updated ESC and ACC/AHA guidelines highlight the role of high-dose icosapent ethyl in lipid management, and these findings could strengthen the clinical positioning of the therapy by improving risk stratification tools.
4. Investor Considerations
Enhanced identification of at-risk patients through RW-apoB may support broader physician adoption and patient identification efforts, potentially driving increased demand for icosapent ethyl and impacting Amarin’s market positioning.
